Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Frovatriptan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B known ✓ | P28222 | 3/20 | 1.00 |
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 0.86 |
| ▸ | DRD4 | P21917 | 1/20 | 0.86 |
| ▸ | HTR1E | P28566 | 1/20 | 0.86 |
| ▸ | HTR7 | P34969 | 1/20 | 0.86 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.86 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.86 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.46 |
| ▸ | HTR1F | P30939 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Frovatriptan SCHEMBL16365906 | 1.00 | HTR1B (1.00) | HTR1BHTR1AHTR1DDRD2DRD4 | |
| Frovatriptan SCHEMBL34410 | 1.00 | HTR1B (1.00) | HTR1BHTR1AHTR1DDRD2DRD4 | |
| Frovatriptan SCHEMBL2456983 | 1.00 | HTR1B (1.00) | HTR1BHTR1AHTR1DDRD2DRD4 | |
| Frovatriptan SCHEMBL3474278 | 0.99 | HTR1B (0.98) | HTR1BHTR1AHTR1DDRD2DRD4 | |
| Frovatriptan SCHEMBL672784 | 0.94 | HTR1B (0.98) | HTR1BHTR1AHTR1DDRD2DRD4 | |
| Frovatriptan SCHEMBL5489168 | 0.94 | HTR1B (0.98) | HTR1BHTR1AHTR1DDRD2DRD4 | |
| Frovatriptan SCHEMBL2321442 | 0.93 | HTR1B (1.00) | HTR1BHTR1AHTR1DDRD2DRD4 | |
| SCHEMBL7030069 | 0.89 | HTR1B (0.80) | HTR1BHTR1AHTR1DDRD2DRD4 | |
| SCHEMBL8018884 | 0.87 | HTR1A (0.78) | HTR1BHTR1AHTR1DDRD2DRD4 | |
| SCHEMBL8018888 | 0.87 | HTR1A (0.78) | HTR1BHTR1AHTR1DDRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024249914-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING DYSTONIA | DUKE UNIVERSITY (US) | 2024-12-05 | — | — | WO | claimed |
| US-20240390364-A1 | Novel Pyridine Compositions and their use in methods for preventing or treating diseases, disorders and conditions | REID CHRISTOPHER BRIAN (US) | 2024-11-28 | — | — | US | claimed |
| EP-4236939-A1 | CRYSTALLINE AND AMORPHOUS FORMS OF A DELTA-OPIOID MODULATOR | Trevena, Inc. (US) | 2023-09-06 | — | — | EP | claimed |
| WO-2022093904-A1 | CRYSTALLINE AND AMORPHOUS FORMS OF A DELTA-OPIOID MODULATOR | TREVENA, INC. (US) | 2022-05-05 | — | — | WO | claimed |
| EP-4475919-B1 | INHALER | 1NHALER LTD (GB) | 2026-04-15 | — | — | EP | disclosed |
| US-20260041775-A1 | COMPOSITIONS FOR DRUG ADMINISTRATION | AEGIS THERAPEUTICS, LLC (US) | 2026-02-12 | — | — | US | disclosed |
| US-20260000693-A1 | SEROTONERGIC PSYCHEDELIC AGENT FOR TREATING SELECTIVE MUTISM | LOBE SCIENCES LTD (CA) | 2026-01-01 | — | — | US | disclosed |
| US-12447294-B2 | Foldable inhaler | 1NHALER LTD (GB) | 2025-10-21 | — | — | US | disclosed |
| EP-4126135-B1 | FOLDABLE INHALER | 1NHALER LTD (GB) | 2025-06-25 | — | — | EP | disclosed |
| US-20250144325-A1 | INHALER | 1NHALER LTD. (GB) | 2025-05-08 | — | — | US | disclosed |
| CN-115315287-B | Foldable inhaler | 1恩哈勒有限公司 | 2025-04-18 | — | — | CN | disclosed |
| EP-4360682-B1 | INHALER | 1NHALER LTD (GB) | 2025-03-26 | — | — | EP | disclosed |
| US-20220387738-A1 | INHALER | 1NHALER LIMITED (GB) | 2022-12-08 | — | — | US | disclosed |
| WO-2022232931-A1 | CATALYTIC TRYPTAMINE PROCESSES AND PRECURSORS | KARE CHEMICAL TECHNOLOGIES INC. (CA) | 2022-11-10 | — | — | WO | disclosed |
| US-11446451-B2 | Inhaler | INHALER LIMITED (GB) | 2022-09-20 | — | — | US | disclosed |
| US-11400048-B2 | Pharmaceutical oil-in-water nano-emulsion | SYNERGIA BIO SCIENCES PRIVATE LIMITED (IN) | 2022-08-02 | — | — | US | disclosed |
| WO-2022093904-A1 | CRYSTALLINE AND AMORPHOUS FORMS OF A DELTA-OPIOID MODULATOR | TREVENA, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
| CN-110831648-B | Inhaler | 1恩哈勒有限公司 | 2022-04-22 | — | — | CN | disclosed |
| WO-2022056475-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING A DYSTONIA | DUKE UNIVERSITY (US) | 2022-03-17 | — | — | WO | disclosed |
| US-20220023551-A1 | METHODS AND DEVICES FOR CONTROLLED DRUG VAPORIZATION | THE TRUSTEES OF PRINCETON UNIVERSITY | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260041775-A1 | COMPOSITIONS FOR DRUG ADMINISTRATION | SLC2A8, SLC5A2, SLC2A4 | HTR1B 87/4885HTR1D 213/4885HTR1A 325/4885 |
| US-20260000693-A1 | SEROTONERGIC PSYCHEDELIC AGENT FOR TREATING SELECTIVE MUTISM | HTR2C, HTR2B, MGMT | HTR1B 4/4885HTR1D 19/4885HTR1A 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.